Their Fc receptors (e.g., CD16) recognise tumour antigen-antibody complexes, mediating antibody-dependent cellular cytotoxicity (ADCC), exemplified by the antitumour effect of anti-human epidermal growth factor receptor 2 (HER2) antibodies in BC (11, 27). This evidence concerns the gene ERBB2 and breast cancer.